Form 4: Baker Bros. Advisors Report Beneficial Ownership Change in Replimune Group, Inc.

Baker Bros. Advisors reported changes in beneficial ownership of Replimune Group, Inc. due to the grant of non-qualified stock options to Michael Goller, a director by deputization.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Replimune Group, Inc.
• The filing reports the grant of 64,000 non-qualified stock options to Michael Goller, a full-time employee of Baker Bros. Advisors LP, on March 5, 2025, in his capacity as a director of Replimune Group, Inc.
• The stock options have an exercise price of $12.29 per share and expire on March 5, 2035.
• 25% of the options vest on March 5, 2026, with the remaining 75% vesting in 24 equal monthly installments thereafter, contingent upon Michael Goller's continued service on the board.
• Michael Goller serves on the board as a representative of 667, L.P. and Baker Brothers Life Sciences, L.P.
• Baker Bros. Advisors LP serves as the investment advisor to these funds and has complete discretion over the investment and voting power of the securities held for their benefit.
• Julian C. Baker and Felix J. Baker, managing members of Baker Bros. Advisors GP, may be deemed to have an indirect pecuniary interest in the stock options.
• The reporting persons are deemed directors by deputization of the Issuer.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The grant of stock options can be seen as a positive sign of aligning interests, but it's a routine event.

Positives

• The grant of stock options to a director aligns their interests with the company's performance.
• The vesting schedule incentivizes continued service on the board.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by significant shareholders and insiders, which is common in the biotechnology industry where stock options are frequently used as compensation.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for directors and employees in the biotech industry, aligning their interests with shareholders.
• Vesting schedules are also typical, encouraging long-term commitment.
• Baker Bros. Advisors is a well-known investment firm specializing in life sciences, and their holdings in Replimune are not unusual given their investment focus.

Management Changes

Stakeholder Impact

• The grant of stock options could potentially incentivize the director to act in the best interests of shareholders.
• The vesting schedule encourages long-term commitment from the director.

Key Dates